Brolucizumab is a humanized single-chain antibody fragment for the treatment of neovascular (wet) age-related macular degeneration (AMD). The most common side effects are reduced visual acuity, cataract (clouding of the lens in the eye), conjunctival haemorrhage (bleeding at the front of the eye) and vitreous floaters (spots in the vision). The most serious side effects are blindness, endophthalmitis (an infection inside the eye), retinal artery occlusion (blockage of the artery in the retina) and retinal detachment (separation of the retina from the back of the eye). Brolucizumab was designed to attach to and block a substance called vascular endothelial growth factor A (VEGF-A). VEGF-A is a protein that makes blood vessels grow and leak fluid and blood, damaging the macula. By blocking VEGF-A, brolucizumab reduces the growth of the blood vessels and controls the leakage and swelling.
This report contains market size and forecasts of Broluzumab Biosimilars in global, including the following market information:
Global Broluzumab Biosimilars Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global Broluzumab Biosimilars Market Sales, 2017-2022, 2023-2028, (K Units)
Global top five Broluzumab Biosimilars companies in 2021 (%)
The global Broluzumab Biosimilars market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period 2022-2028.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Beovu Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Broluzumab Biosimilars include Novartis, Genentech, Roche, Pfizer, Sartorius, Eli Lilly, Bayer, Amgen and PlantForm, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Broluzumab Biosimilars manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Broluzumab Biosimilars Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Broluzumab Biosimilars Market Segment Percentages, by Type, 2021 (%)
Beovu
Vsiqq
Others
Global Broluzumab Biosimilars Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Broluzumab Biosimilars Market Segment Percentages, by Application, 2021 (%)
ARMD
Kaposi Sarcoma
Glioblastoma
Global Broluzumab Biosimilars Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Broluzumab Biosimilars Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Broluzumab Biosimilars revenues in global market, 2017-2022 (Estimated), ($ millions)
Key companies Broluzumab Biosimilars revenues share in global market, 2021 (%)
Key companies Broluzumab Biosimilars sales in global market, 2017-2022 (Estimated), (K Units)
Key companies Broluzumab Biosimilars sales share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Novartis
Genentech
Roche
Pfizer
Sartorius
Eli Lilly
Bayer
Amgen
PlantForm
PharmaPraxis
Samsung Bioepis
Centus
Cadila Pharmaceuticals
Dr Reddy's
Aurobindo Pharma
Biocad
MAbxience
Hetero
Biocon
Kirin Biologics
Mylan
BeiGene
Innovent
Qilu Pharmaceutical
Hengrui Pharmaceuticals
Hisun Pharmaceutical
TOT BIOPHARM
Luye Pharmaceutical
Henlius